Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study

NCT06506955 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT06506955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06506955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
October 1, 2024
Completion date
April 30, 2027
Enrollment
15 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic cancer